Table 1.

Clinical and molecular features of patients with CML

PatientPhaseMutationsIM statusLIG3 upPARP1 upc-MYC up
1ChronicNoneSensitiveYYY
2ChronicNoneSensitiveYYN
3ChronicNoneResistantYYY
4ChronicNoneSensitiveYNN
5ChronicNoneSensitiveNNN
6aBlast crisisNoneResistantYYY
7Blast crisisNoneResistantNNN
8aBlast crisisT315IResistantYYY
9AcceleratedNoneResistantNNN
10UnknownUnknownUnknownNYY
11ChronicNoneResistantYYY
12ChronicNoneResistantYYY
13aChronicNoneSensitiveYYY
14ChronicNoneSensitiveYYY
15Blast crisisNoneResistantNYN
16Blast crisisT315IResistantYYY
17aBlast crisisNoneSensitiveNNN
18aBlast crisisNoneResistantNNN
19aChronicNoneSensitiveNNY
20aBlast crisisNoneResistantNNN
21aBlast crisisT315IResistantNNY

NOTE: Increased LIG3, PARP1 and c-MYC expression relative to normal control bone marrow MNC and based on P < 0.05 by the t test.

Abbreviations: IM, imatinib; N, no; Y, yes.

  • aPatient samples used for miRNA analysis.